Access based on positive interim analysis of clinical data as well as preclinical data to date PRIME designation provides a pathway for frequent and early interactions with the EMA aimed at supporting accelerated evaluation and approval
… ProQR’s Drug Candidate QR-110 for Leber’s Congenital … LEIDEN, the Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that … mutation,” said Daniel de Boer, Chief Executive Officer of ProQR. “Obtaining orphan drug designations from EMA and FDA …
Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a virtual Analyst Event.
… ProQR Announces Annual Meeting of Shareholders LEIDEN, the … be made available in the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘ Financial Information ’. The …